Intellectual Property: Valuation, Exploitation and Infringement Damages 2013 Cumulative Supplement, 11th Edition

INDEX

Advertising and trademarks, 11–12

ANAQUA software, 157

Arm's-length pricing, 136

Assets. See also Intellectual property and intangible assets (IP&IA)

tangible vs. intangible, 4–5, 26, 144

Assumed (virtual) transactions, 82, 186–188

Assumptions

in appraisals, 83

assumed transactions, 82, 186–188

in expected cash flow approach, 35

Monte Carlo runs, 66

in patent infringement, 186, 188

in post-judgment royalty, 194

Audits, 141–161. See also Management of IP assets; Royalty misreporting

about the data presented, 130, 132–133

agreements included, 154–155, 158–161

assets included, 153–154, 158–161

checklist for, 158–161

definition, 144

event-driven audits, 151–152

frequency of, 146, 150–152

general-purpose audits, 150–151

how to do, 152–155

limited-purpose focused audits, 152

reasons for, 144–145

results of, 145–146

software for, 155–158

of trade secrets, 14, 153–154, 160

transfer price errors and, 136

Bard Peripheral Vascular, Inc. v. W. L. Gore, Inc., 189, 195–198

Base. See Royalty base

Bayes, Thomas, 72

Bayesian analysis, 63, 72–75

Bayes' theorem, 72

Benchmarks and milestones

Royalty Rates for Technology, 116

unreported, 132, 133, 137

Beta, 36–37, 41

Biotechnology companies' reasons for licensing, 17–19

Biotechnology royalty rates, 121–128, 253–276

aldurazyme, 254–256

anti-hypertension therapy, 256–258

attention deficit hyperactivity disorder, 258–259

blood expander, 260–264

cancer, 264–268

corporate involvement, 122

developmental stages of technology, 126–128, 137, 253–254 ...